PATIENT AI Act Discussion Draft, AMA Issue Brief for Clinical AI Liability Released
Accountability and reimbursement for artificial intelligence (AI)-based technologies were highlighted topics of discussion last week.
The Centers for Medicare & Medicaid Services (CMS) recently clarified Clinical Laboratory Improvement Act (CLIA) certification requirements for remote cytology.
The College of American Pathologists (CAP) requested clarification because of recent federal policy updates, including updates to requirements related to CLIA certification for laboratories. CMS officials explained that remote Rapid Adequacy Assessments (also known as rapid on-site evaluation or ROSE) require a separate CLIA certificate for an off-site location where a review is performed, including virtual slide review. CMS also clarified that adequacy assessment does not count as a separate examination for workload limit purposes.
Source:
https://www.cap.org/advocacy/latest-news-and-practice-data/march-31-2026#story2
Accountability and reimbursement for artificial intelligence (AI)-based technologies were highlighted topics of discussion last week.
Lincoln, NE – November 2026 TELCOR is proud to announce the promotion of Stephanie Gonnerman to Senior Analyst, Revenue Cycle Management (RCM).
The Centers for Medicare and Medicaid Services (CMS) released a report on Oct. 20 detailing significant differences in the share of reported test...